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Case Report
B-Cell Lymphoma of the Brainstem with Central Neurogenic Hyperventilation
Syed Ather Enam,1 Rushna Ali2
Section of Neurosurgery,1 Medical Student,2 Aga Khan University Hospital, Karachi.
Abstract
Non-Hodgkin's lymphoma of the brainstem is a rare
entity. Central Neurogenic Hyperventilation (CNH), an
associated manifestation of this disease, is an even rarer
event. We report a case of an immunocompetent individual
who presented to us with tachypnea and facial nerve palsy.
Neuroimaging showed a Cerebellopontine angle tumour
which on histopathology showed feature consistent with a
Non-Hodgkin's B-Cell Lymphoma. The patient went on to
develop severe respiratory alkalosis with findings consistent
with CNH. Chemotherapy with Methotrexate was started and
high dose Dexamethasone was added to the regimen a month
later. Radiologically, the tumour size decreased by 50% but
the patient's clinical condition deteriorated. He eventually
expired due to cardiopulmonary arrest. Some common
clinical presentations of this disease and various diagnostic
modalities and treatment options available to such patients
are discussed.
Keywords: Brainstem, Central Neurogenic
Hyperventilation, Lymphoma.
Introduction
Primary CNS lymphoma (PCNSL) is a rare form of
extra-nodal non-Hodgkin's lymphoma, accounting for 4% of
all primary brain tumours. It affects the brain, leptomeninges,
spinal cord and the eyes. It remains confined to CNS in
majority of the cases.1 Localization primarily in the brainstem
occurs in 3% of PCNSL and most are T-Cell in origin.2 The
only established risk factor is congenital or acquired
immunodeficiency. Only 1.9-6% of patients afflicted with
AIDS develop PCNSL.2 In the past few years, there has been a
threefold increase in the incidence of PCNSL in
immunocompetent individuals. Tumour induced CNH in an
awake patient is a rare manifestation of this disease.3 To date,
only a few cases have been reported. We report a case of
Primary Brainstem B-cell Lymphoma in an immunocompetent
individual who eventually developed CNH.
Case Report
A 47 year old man, known case of Chronic
Obstructive Pulmonary Disease and Hypertension was
presented to the ER, with a history of shortness of breath,
fever and headache for 3 days. He also developed recurrent
left-sided facial weakness which had started 2 months earlier.
There was no other significant past history be it medical,
surgical, drug or family. On general physical examination he
was tachypnoeic with a respiratory rate of 47 breaths/minute.
He was otherwise vitally stable. Cardiovascular,
genitourinary, gastrointestinal and immunologic reviews
were all negative. On chest examination diffuse bilateral
crackles were present. On facial nerve examination there was
left sided facial drooping with flattening of naso-labial fold,
weak gag and inability to close the left eye. Motor
examination showed left-sided motor paresis grade 4/5 in
both upper and lower limbs. Rest of the neurological
examination was unremarkable. His Karnofsky performance
score was 50.
A CT scan brain was done one month prior to
admission which showed a hypodense irregular lesion in left
cerebellum measuring 2.5x1.8cm. It was suspected to be an
intrinsic cerebellar or cerebello-pontine (CP) angle tumour.
Further treatment and investigations were deferred by the
patient and his family. The patient was admitted with the
provisional diagnosis of pneumonia with left sided CP
tumour and empirically started on Anti-Tuberculous therapy,
antibiotics and hydrocortisone.
Initial Complete Blood Count (CBC) and Serum
Electrolytes results revealed no abnormality. TSH, Creatinine
and Liver function tests were normal. HIV, Hepatitis B and
Hepatitis C serology were all nonreactive. Initial CSF
analysis did not reveal any abnormalities.
A contrast enhanced Magnetic Resonance Imaging
(MRI) scan of the brain showed a mass lesion measuring
3.2x2.5x2.5cm in left cerebellar peduncle extending into the
medulla and midbrain. It showed homogenous enhancement
with gadolinium and diffuse meningeal enhancement. There
were no signs of hydrocephalus, areas of recent infarction or
intracranial haemorrhage.
A sub-occipital craniotomy was performed to obtain a
sample for biopsy. Histopathology showed a neoplastic lesion
with cells predominantly arranged around blood vessels
exhibiting cellular atypia, nuclear pleomorphism,
hyperchromasia and increased mitotic activity. The GFAP,
LCA, PAN-B and Ki-67 tumour markers were positive.
These findings were suggestive of a High Grade Non-
Hodgkin's B-cell lymphoma of large cell type. Smears for
Fungi and Acid Fast Bacilli were negative. Bone Marrow
Aspirate and Trephine showed no evidence of lymphomatous
infiltration of the bone marrow. CT Chest, Abdomen and
Pelvis were performed to check for organ metastasis and
lymphadenopathy, all of which revealed no disease.
The ATT was discontinued and combination
chemotherapy was begun. The patient received ATT only for
a period of 10 days, which is too short a time to assess its
efficacy. The patient however showed no clinical
improvement with it. Chemotherapy with Methotrexate
2.5g/m2 alternating with Vincristine was begun. A month later
high dose Dexamethasone was added to the regimen. During
his hospital stay the patient had multiple progressively
worsening episodes of hyperventilation which persisted
during sleep. He developed respiratory alkalosis with ABGs
showing pH, 7.54; pCO2 30.2mmHg and pO2 147.6mmHg.
No metabolic cause for his tachypnoea could be discerned
and his Chest Radiography, ECG and Echocardiography were
normal. His tachypnoea persisted with repeat ABGs showing
pH of 7.51, pCO2, 25.6mmHg and pO2 92mmHg. The
findings suggested the diagnosis of Central Neurogenic
Hyperventilation (CNH) due to brainstem infiltration.
Midazolam resulted in immediate reduction of respiratory
rate but it's effect was transient and repeated administration
was necessary. He subsequently developed generalized tonic-
clonic seizures and septic shock despite being on multiple
antibiotics and antiepileptic medication. He had to be shifted
to the intensive care unit where he was mechanically
ventilated. A repeat MRI showed a 50% reduction in size of
lymphoma after receiving 4 cycles of chemotherapy.
However, the patient's clinical condition progressively
deteriorated. Despite intensive investigations we could not
discern a plausible cause for this disparity between a good
radiological response but worsening clinical condition. His
status was discussed with his family and he was declared Do
Not Resuscitate (DNR). The decision not to institute any
form of radiotherapy was based on the patients weakened
state and his personal as well as his family's wishes. No
benefit of an alternative therapy could be foreseen since the
tumour had significantly decreased in size and seemed to be
vigorously chemo-sensitive. He went into cardiopulmonary
arrest after 2 months of receiving intensive in-patient care and
expired.
Discussion
In immunocompetent patients PCNSL typically
occurs during the 6th and the 7th decade of life and presents
with focal findings. The data of 378 PCNSL patients was
collected by The International Extranodal Lymphoma study
group. It revealed that the frontal lobe was involved in 44%,
parietal lobe in 13%, temporal lobe in 14%, occipital lobe in
6%, basal ganglia in 28%, brainstem in 6%, cerebellum in
6%.4 Approximately 90% of PCNSLs are Diffuse large B-
Cell Lymphomas; the remaining 10% are poorly
characterized by low-grade lymphomas, Burkitt's lymphomas
and T-Cell lymphomas.5 However, the brainstem shows a
penchant for T-Cell lymphomas.3 The median age at
diagnosis is 53-57 years with a male-to-female ratio of 1.2 to
1.7:1.5
In a study that focused on the clinical presentations of
248 immunocompetent patients with PCNSL. The authors
reported that 70% had focal neurological deficits, 43% had
neuropsychiatric symptoms, 33% had raised intracranial
pressure, 14% had seizures and 4% had ocular symptoms.6
Our patient had the most common clinical presentation of
focal neurological deficit in the form of facial nerve palsy.
Lumbar puncture with CSF sampling should be
performed at the time of initial assessment in patients with
suspected PCNSL. In a study of 96 patients with newly
diagnosed PCNSL, the initial CSF cytological studies were
positive in only 15%.7 However, in another study two-thirds
of PCNSL patients who developed positive CSF cytological
findings had negative results on an initial examination,
suggesting that the serial CSF samples would result in
increased diagnostic sensitivity.7 CSF sampling in our patient
was deferred due to prior radiological evidence of a space-
occupying lesion in the posterior fossa.
Contrast enhanced MRI is the optimal imaging
modality for assessing these patients. The lesions are
isointense or slightly hypointense in T1-weighted images and
slightly hyperintense in T2-weighted images. About 75% of
immunocompetent patients show an intense homogeneous
enhancement after contrast administration. On CT scan
PCNSL are isodense or slightly hyperdense with a mild mass
effect, showing homogeneous enhancement after contrast
administration.8 Consistent findings were present in our
patient.
Five year survival approaches 4% of patients with
primary malignant lymphomas.2 If untreated, the median
survival is only 4.6 months.9 A unique feature of PCNSL
compared with other brain tumours is its unique sensitivity to
steroids. The steroids have a direct cytotoxic effect but purely
steroid-induced remission is short-lived in most patients.
However 40% of the patient's tumour shrinks or disappears
with an administered combination of steroids and whole brain
radiation therapy (WBRT).9 Radiation and steroid treatment
lead to a median survival of 12-18 months. In the last decade
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several phase II studies have shown that the 5-year actuarial
probability of survival with certain chemotherapy regimens
followed by WBRT is approximately 28%-40%. This is
superior to the reported 2-year survival of 28% with WBRT
alone. The primary Chemo therapy (CHT) regimen in
PCNSL should include Intravenous High Dose methotrexate,
the most effective drug against these malignancies in lieu of
its ability to cross the Blood Brain Barrier.1 In a recent study,
addition of cytarabine produced a statistically significant
improvement in survival.10 Stereotactic radiosurgery as a
treatment option for PCNSL has only been recently explored
and reported in the literature.9
Our patient had the unique feature of Central
Neurogenic Hyperventilation (CNH) associated with his
tumour. Diagnostic criteria for CNH are hyperventilation that
persists during sleep, low arterial PaCO2, high arterial PaO2
and high arterial pH in the absence of drugs or metabolic
causes.3 CNH results from the uninhibited stimulation of both
inspiratory and expiratory centers in the medulla by the
lateral pontine reticular formation and by laterally located
descending neural pathways. Of the 21 cases of CNH
reported in the literature, all were associated with either an
infiltrative brainstem lesion or diffuse cerebral involvement.
Out of the 18 reported cases that specified tumour
histopathologic features, there were 9 with lymphoma, 6 with
slow-growing astrocytoma, 1 with metastatic tumour, 1 with
medulloblastoma and 1 with aggressive astrocytoma.3
Despite the highly responsive nature of PCNSL to
initial treatments, local control remains the largest obstacle in
the treatment of this disease. Recurrence occurs in more than
90% of patients, most commonly in the brain.7 In conclusion,
PCNSL is a rare malignancy; however, the extraordinary
frequency of primary cerebral lymphoma among the few
patients with tumour induced CNH suggests that lymphoma
must be high in differential diagnosis and should guide
therapy.3 If there is a suspicion of a lymphoma, steroid
therapy should be avoided as it can cause radiological and
clinical improvement in the patient, but making the
histopathological confirmation undesirable. Thus delaying
diagnosis. The variable clinical presentation and poor
prognosis associated with PCNSL warrant a prompt and
critical evaluation of these patients followed by aggressive
and multidisciplinary treatment approach.
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